All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
During the EHA 2022 Congress, the MDS Hub was pleased to speak to Theo de Witte, Radboudumc, Nijmegen, NL. We asked, How do we differentiate high-risk MDS from AML?
How do we differentiate high-risk MDS from AML?
De Witte begins by explaining the implications of the new International Prognostic Scoring System (IPSS) for MDS, and the flaws of existing risk-based scoring systems. De Witte then discusses the data from the patient cohort used to develop the new IPSS, including the most relevant genetic predictors of adverse and favorable outcomes. De Witte also talks about the parameters that can be given by the IPSS calculator.
EHA2021 practice-changing abstracts in myelodysplastic syndromes
World-leading experts in MDS shared the top abstracts from the EHA2021 Virtual Congress that they believed could have the greatest impact on clinical practice.
Practice-changing abstracts in myelodysplastic syndromes
World-leading experts in MDS shared the top abstracts from ASH 2020 that they believed could have the greatest impact on clinical practice.
Subscribe to get the best content related to MDS delivered to your inbox